Monitoramento da Adesão e Eficácia de Produtos Cosméticos
publicado em 01/10/2002
Dr. Almuth M. Koehler e Dr. Howard I. Maibach
Faculdade de Medicina da University of California, San Francisco CA, Estados Unidos
Neste artigo os autores discutem a importância da adesão dos voluntários aos testes de eficácia e as maneiras de controlá-la.
The authors describe the importance of the patient adherence to the efficacy tests and the manners to controI it.
En este articulo los autores describen la importância de la adhesion de los voluntarios a los testes de eficácia y sus maneras de contralarla.
Monitoramento da Adesão
Monitoramento Eletrônico
Eficácia de Formulações Tópicas
Conclusão
O cumprimento das prescrições, hoje em dia mais propriamente chamado de adesão, está reconhecidamente desempenhando um papel no processo de tratamento com medicamento.1 É bem conhecida a correlação entre adesão ao tratamento e os resultados.
Portanto, uma diferenciação entre não-adesão e não-resposta é um tema fundamental no desenvolvimento de produtos cosméticos e farmacêuticos mais eficazes e mais adequados.1 Da mesma forma, a influência dos hábitos de adesão sobre a eficácia do tratamento deveria ser muito bem examinada na terapia dermatológica, dermatologia cosmética e desenvolvimento mercadológico de produtos cosméticos.
Para visualizar o restante do artigo faça seu login ou então se cadastre gratuitamente e acesse todo o conteúdo disponível.
1. Urquhart J. The electronic medication event monitor: lessons of pharmacotherapy, Clin Pharmacokinet 32(5):345-356, 1997
2. Urquhart J e de Klerk E. Contending paradigms for the interpretation of data on patient compliance with therapeutic drug regimens, Statistics in Medicine 17:251-267, 1998
3. Rudd P e Lenert L. Pharmacokinetics as an aid to optimizing compliance with medications, Clin Pharmacokinet 28(1):1-6, 1995
4. deKlerk E, van der Linden S, van der Heijde e Urquhart J. Facilitated analysis of data on drug regimen compliance, Statistics in Medicine 16:1653-1664, 1997
5. www.medtrac.com (8 de agosto de 2000)
6. Milgrom H, Bender B, Ackerson L, Bowry P, Smith Be Rand C. Noncompliance and treatment failure in children with asthma, J Allergy Clin Immuno/98:1051-1057, 1996
7. Product information on packaging of Aardex EDEM electronic Drug Exposure Monitor, produced by Aardex Ltd. Union City, CA, USA; see also www.aardexus.com (8 de agosto de
2000)
8. Cramer JA. Microelectronic systems for monitoring and enhancing patient compliance with medication regimens, Drugs 59(3):321-327, 1995
9. Urquhart J. Role of patient compliance in clinical pharmacokinetics: Review of recent research, Clin Pharmacokinet 27(3):202-215, 1994
10. Meredith PA. Therapeutic implications of drug "holidays", European Heart Journal 17(Suppl A}:21-24, 1996
11. Witkowski JA. Compliance: the dermatologic patient, Int J Dermatol 27(9}:608-61 1, 1988
12. Sherertz FE. Pharmacology 1: Topical therapy in dermatology. J Am Acad Dermatology 21(1):108-114, 1989
13. Anastasio GD, Little JM, Robinson MD, Pettice YL, Leich BB e Norton HJ. Impact of compliance and side effects on the clinical outcome of patients treated with oral erythromycin, Pharmacotherapy 14(2):229-234, 1994
14. Piacquadio D e Kligman A. The critical role of the vehicle to therapeutic efficacy and patient compliance, J Am Acad Derm 39(2/Part 3 Suppl):567-573, 1998
15. Schmidt MH e Korting HC. Liposomes: a drug carrier system for topical treatment in dermatology. Crit Rev Ther Drug Carrier Syst 11(2-3):97-118,1994
16. Pflugshaupt C. Grundprinzipien der dermatologischen Lokaltherapie, Ther Umsch 55(8):470-477, 1998
17. Kastrissios H e Blashke TF. Medication compliance as a feature in drug development, Ann Rev Pharmacal Toxicol 37:451-475, 1997
18. Draelos ZD. New developments in cosmetics and skin care products, Adv Dermatol 12:3-17, 1997
19. Quelle-Roussel C, Dahan C, Poncet M, Schaefer H, Revuy J, De Prost Y, Guillaume JC, Ortonne JP e Czernilewski J. Clinical trials in dermatology. Evaluation of the tolerability and efficacy of a topical anti-inflammatory treatment in atopic dermatitis, Therapie 46(3):193-196, 1991
20. Dahan C, Quelle-Roussel C, Verschoore M, Schaefer H, Revuz J, De Prost Y, Guillaume JC, Ortonne JP e Czelmielewski J. Clinical trials in dermatology. Evaluation of the tolerability and efficacy of topical antipsoriatic treatment, Therapie 46(3):197-200, 1991
21. QueIJe-Roussel C, Dahan C, Dutell L, Schaefer H, Revuy J, De Prost Y, Guillaume JC, Ortonne JP e Czemielewski. Clinical trials in dermatology: evaluation of the tolerability of topical antifungal agent in the treatment of superficial mycosis, Therapie 46(3}:201-204, 1991
22. Verschoore M, Poncet M, Schaefer H, Revuz J, De Prost Y, Guillaume JC, Ortonne JP e Czemielewski J. Clinical trials in dermatology. Evaluation of the tolerability and efficacy of an anti-acne, Therapie 46(3):189-191, 1991
23. Cramer J, Vachon L, Desforges C e Sussman NM. Dose frequency and dose interval compliance with multiple antiepileptic medication during a controlled clinical trial, Epilepsia36:111-117, 1995
24. McKenney JM, Munroe WP e Wright JT. Impact of an electronic medication compliance aid on long-term blood pressure control, J Clin Pharmacal 32(3):177-283, 1992
25. Urquhart J. Can drug delivery systems deliver value in the new pharmaceutical marketplace? J Clin Pharmacol 44:413-419,1997
26. Nides MA et al. Improving inhaler adherence in a clinical trial through the use of the nebulizer chronolog, Chest 104:501-507, 1993
27. Feldman HI, Hackett M e Bilker W. Potential utility of electronic drug compliance monitoring in measures of adverse outcomes associated with immunossupressive agents, Pharmacoepidemiology and Drug Safety 81-14, 1999
28. Didlake RH et al: Patient noncompliance: a major cause of late graft failure in cyclosporine-treated renal patients, Transplant Proc 20:63-69, 1988
29. Kass MA, Meltzer D, Gordon M, Cooper D e Goldberg J. Compliance with topical pilocarpine treatment, Am J Ophthalmol 101(5}:515-523, 1986
30. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, Wagener MM e Singh N. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection, Ann Intern Med 133(1}:21-30, 2000
31. Osborne JE e Hutchinson PE. The importance of accurate dosage of topical agents. a method of estimating dosage and its application to apparent calcipotrial treatment failurein psoriasis, Brit J Dermatol 143(Suppl 57):42-85, 2000
32. Kass MA, Meltzer DW e Gordon M. A miniature compliance monitor for eyedrop medication, Arch Ophthalmol 102(10):1550-1554, 1984
Deixar comentário
Para comentar é preciso fazer login no sistema.